DAFTAR PUSTAKA
1. Ferdiansyah T, Sofian A, Fatmawati. Hubungan tumor marker CA-125
dengan sifat dan tipe sel tumor ovarium di RSUD Arifin Achmad
Pekanbaru. [Internet]. 2014 Apr.
2. Maria BAP. Profil penderita tumor ganas ovarium di RSUP Haji Adam
Malik Medan pada tahun 2012. [Internet]. 2014: 1-5.
3. Winata GS. Peran klinis CA-125 pada kanker ovarium. [Internet]. 2014 :
1-15.
4. Sarojini S, Tamir A et al. Early detection biomarkers for ovarian cancer.
Int J Of Onc [Internet]. 2012 [cited 2016 Mar 24]
5. Mulawardhana P, Askandar B, Soehatno. Perbandingan antara HE,
CA-125 dan kombinasi HE4 & CA-CA-125 sebagai tumor marker pada pasien
kanker ovarium tipe epitelial. Int J Obs & Gin Unair [Internet]. 2011 Aug
[cited 2016 Mar 23] :19 :81-83.
6. Harahap Sri D. Kadar angiostatin pada urin penderita tumor ovarium epitel
jinak dan tumor ovarium tipe epitel ganas.[Internet]. 2014 : 1-2.
7. Gupta D, Christopher G. Role of CA 125 in predicting ovarian cancer
survival-a review of the epidemiological literature. Int J Of Ovar Res.
2009 Oct 9: 2(13): 1-20.
8. George GTK. CA-125 : Reference range, interpretation, collection and
panels. [Internet]. 2015 Oct 30 [cited 2016 Mar 28].
9. Ali A. Sensitivitas & spesifisitas human epididymis protein-4 (HE4) dan
antigen kanker CA125 sebagai biomarker pada tumor ovarium jinak dan
ganas di RSUP. H. Adam Malik Medan. [Internet]. 2012 Jul 5 : 1-3.
10.Aziz FM, Andrijono, Saifuddin BA. Buku acuan nasional onkologi
ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006.
11.Chandranita AI, Fajar GBI, Gede BI. Buku ajar penuntun kuliah
ginekologi. Jakarta : Trans Indo Media ; 2010.
12.World Health Organization. WHO classification of tumours of
reproductive organ. 4th ed. World Health Organization; 2014.
13.Tidy C. Benign ovarian tumours. [Internet]. 2015 Jan 14[cited 2016 May
6]. Available from : http://patient.info/pdf/1855.pdf#
14.Foundation For Women’s Cancer. Understanding CA 125 levels. Chicago:
Foundation For Women’s Cancer; 2011.
15.Bast RC, Spriggs DR. More than a biomarker : CA125 may contribute to
ovarian cancer pathogenesis. Int J Gyn Onc Elsev [Internet]. 2011 [cited
2016 May 6] : 429-430.
16.Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et
al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin
mediates cell adhesion. Int J Of Bio Chemis [Internet]. 2004 Mar 5.
17.Theriault C, Pinard M, Comalama M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Int J Gyn Onc Elsev [Internet]. 2011 Mar 21 [cited 2019 May 6] : 434-443.
18.Rarung M. Sensitifitas dan spesifisitas petanda tumor CA-125 sebagai
prediksi keganasan ovarium. [Internet]. 2005.
19.Kaloo PD, Cheltenham, Louden KA, Winchester, Khazali S, Hoy D, et al.
Management of suspected ovarian masses in premenopausal women. Int
Roy Coll Of Obs & Gyn [Internet]. 2011 Nov 1 [cited 2016 May 6].
peritoneum: abridged republication. J Gynecol Oncol. 2015; 26 (2): 87-89.
22.Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F,
et al. Development of a multimarker assay for early detection of ovarian
cancer. J Clin Oncol, 2010; 28: 2159-2166.
23.Jordan SM, Bristow RE. Ovarian cancer biomarkers as diagnostic triage
test. Current biomarker findings 2013; 3: 35-42.
24.Kumar V, Abbas A, Fausto N, Aster J, Robbins, Cotran. Pathologic basis
of disease. 8th ed, Saunders Elsevier, Philadelphia,2010.
25.Nurlailiyani. Hubungan antara usia pasien dengan derajat keganasan tumor
ovarium primer di RSUD DR. Moewardi tahun 2011-2012. [internet],
2013; 51.
26.Calster B, Timmerman D, Bourne T, Testa AC, Holbese C, Domali E, et
al. Discrimination between benign and malignant adnexal masses by
specialist ultrasound examination versus serum CA-125. J Natl Cancer
Inst, 2007; 99(22) : 1706-1714.
